First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

The goal of this study is listed below. Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%. Part B (Randomization Phase) : To evaluate the efficacy of pembrolizumab and nesuparib combination/ pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator

Trial Details

NCT ID
NCT06502743
Phase
PHASE2
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Nesuparib
  • Pembrolizumab
Locations (sample)
  • Seongnam-si, Gyeonggi-do, South Korea|37.43861,127.13778
  • Goyang-si, Kyeonggi-do, South Korea|37.65639,126.835
  • Seoul, Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Patient must be female ≥ 19 years of age
  • Histologic confirmation of the original primary tumor is required. Patients with the following histologic types are eligible: Endometrioid adenocar…
  • Measurable stage III, measurable stage IVA, stage IVB-IVC (with or without measurable disease) or recurrent (with or without measurable disease) en…
  • MMR proficient confirmed by institutional (local) MMR IHC testing using a 4-marker panel(MSH2, MSH6, PMS2, MLH1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →